Talk:Paliperidone
This is the talk page for discussing improvements to the Paliperidone article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Paliperidone.
|
Paliperidone
[edit]Paliperidone is the brand name of an extended release formula of the longer acting 9-hydroxy metabolite of the antipsychotic known as Risperidone. Since some of the activity of risperidone is due to this active metabolite, one would expect there to be many similarities in effiacy and adverse effects between risperidone and paliperidone. Since it is a new and unique compound, it is still given patent protection. It is unclear as of yet what advantages, if any, it has over the parent compound. Since some of the effects of risperidone are due to the actual "parent" drug, there may be some differences between the two drugs but it is unclear as of yet whether or not this is the case. It is due to be released by or in early 2007.
Paliperidone is the major active metabolite of risperidone, it is differentiated from risperidone by the addition of one hydroxy group. It is certainly going to be licenced/marketed as a different drug and will nicely provide Janssen with a patented drug once Risperdal loses its. Colin°Talk 20:18, 4 June 2006 (UTC)
That's a common enough technique for trying to extend patent protection. If we are sure the drug is confirmed then I guess it can have its own page; it needs the info box with the proper structure and prominent links to risperidone. However, since all the prescribing and side-effect info will the same at least for a few years (until and if paliperidone turns out to have different effects when its in wide use) it would still also make sense to keep it in one article. I guess I could go either way. Thatcher131 05:30, 5 June 2006 (UTC)
can any1 tell me y paliperidone is developed as using OROS tech?
Amit Gupta
[email protected]
Paliperidone vs. Risperidone
[edit]Not that I have any medical credentials, but I have read that risperidone metabolizes into a number of non-paliperidone components which could potentially cause side-effects. By taking paliperidone such side-effects would be avoided. It might be safe to say that paliperidone is a "purified" risperidone.
72.192.204.89 01:37, 15 August 2007 (UTC)
many doctors are fooled by this as well. Ther is nothing "pure" about invega. it is a metabolite of risperdal, delveloped, likely to extend the patient that expired on risperidone. The purity of compound depends on what it mixed with when it is manufactured. Risperdone, may have other metabolies, but a 'pure' sample of Risperidone and invega are both possible.... i hope that makes sense. The pharm reps will tell you different —Preceding unsigned comment added by 75.63.235.124 (talk) 21:23, 14 February 2010 (UTC)
Rumor
[edit]I was told Invega was a reverse isotope of Risperidone (sold as Riperdol 2) ;) I bet my doctor was wrong. Yeah, I took it. —Preceding unsigned comment added by 72.23.108.110 (talk) 07:51, 21 November 2007 (UTC)
Structure and name are lacking a stereocenter
[edit]I believe the name is: (9R)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[2,1-b]pyrimidin-4-one and the structure should be reflected to display that. See the molecule here: http://www.chemspider.com/Chemical-Structure.7978307.html —Preceding unsigned comment added by ChemSpiderMan (talk • contribs) 03:28, 22 May 2008 (UTC)
- Will fix this as soon as I get to my main computer (i.e. the one with ChemSketch :) Fvasconcellos (t·c) 17:02, 25 May 2008 (UTC)
- Done. Fvasconcellos (t·c) 14:34, 29 May 2008 (UTC)
Possible copyright violation
[edit]At this version, the page is very similar to the link given at the bottom: http://www.prescribingreference.com/products/showProducts/which/Invega, for which what appears to be a privately held company holds a copyright. (See the section on Adverse Reactions.) modify 03:34, 22 May 2008 (UTC)
- Removed. Since it was accurate information, it should be reworded and returned to the article eventually. Fvasconcellos (t·c) 17:09, 25 May 2008 (UTC)
Janssen vs Janssen-Cilag
[edit]this article references Jannsen pharmaceuticals, while the older risperdone article mentions Janssen-Cilag, but not until i went to the Cilag page was the reference made clear, the marketing company goes by the name janssen-Cilag, while products are marketed as either Janssen of cilag, depending on what the product is and where in the world it's being sold. It's a bit confusing the way the pages are now, if you don't read the section in cilag, which is only really marketed in europe, then you just wonder why there is a stub article link on the risperdone page.Kesuki (talk) 02:15, 22 July 2008 (UTC)
Stereochemistry incorrect
[edit]Please note, that paliperidone (as pharmaceutical product) is not a single enantiomer. It's a racemate of both (R) and (S) enantiomers; see e.g. full INVEGA U.S. Prescribing Information:
"INVEGA®
contains a racemic mixture of ( )- and (-)- paliperidone. The chemical name is (±)-3-[2-[4-
(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4
H-pyrido[1,2-a]pyrimidin-4-one."
(accessed on December 3, 2008). No idea why ChemSpider displays the (R) enantiomer. Cheers.--84.163.111.35 (talk) 05:27, 3 December 2008 (UTC)
- ... will be corrected soon. --Jü (talk) 08:11, 16 August 2009 (UTC)
- ... done. Best regards, --Jü (talk) 15:07, 16 August 2009 (UTC)
Possible Copyright Violation
[edit]In the pharmacology section it is stated that Invega will be marketed for bipolar mania. What is the source for this I was unable to find it.
I also don't understand this part "The drug significantly reduces side-effects present in other anti-psychotic drugs formerly used to treat both schizophrenia as well as bipolar disorder[citation needed]." Invega's side effects are just as bad as all the other atypical antipsychotics. In fact Invega's most common side effects are headache (no big deal) and tachycardia (big deal). Really the only thing that makes Invega any better than Risperdol is that the Invega doesn't have to be so hard core processed by your liver.
Girrl88 (talk) 17:23, 8 March 2009 (UTC)
Edited to clarify -
Where it says "Invega will be marketed for bipolar mania" If you do have a reference link then please post it.
Also, the part that says, "The drug significantly reduces side-effects present in other anti-psychotic drugs formerly used to treat both schizophrenia as well as bipolar disorder". That still makes no sense. Is this trying to say that the side effect profile for Invega isn't as bad as the other antipsychotic meds? When I read the sentence it seems to say that Invega will reduce the side effects of the other atypical antipsychotics that you are taking.
Girrl88 (talk) 22:04, 23 May 2009 (UTC)
more info
[edit]Here's some more information about invega which should be useful. http://www.nature.com/mp/journal/v13/n1/full/4002066a.html 150.203.110.137 (talk) 18:24, 15 August 2009 (UTC)